We recently compiled a list of the Retirement Stock Portfolio: 7 Safe Dividend Stocks To Invest In. In this article, we are ...

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday ...

AbbVie and Nimble Therapeutics have announced an acquisition deal in which AbbVie will gain ownership of the company’s ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

AbbVie Inc. closed $31.94 below its 52-week high ($207.32), which the company achieved on October 31st.

(RTTNews) - AbbVie Inc. (ABBV), Thursday announced that the Canadian Headache Society's newly updated Migraine Prevention Guideline has strongly supported the usage of Atogepant for episodic and ...

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

AbbVie (NYSE:ABBV – Get Free Report) had its price objective raised by analysts at Piper Sandler from $212.00 to $220.00 in a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on ...

Nimble Therapeutics, formerly NimbleGen Systems, is developing an oral therapy that could treat psoriasis and inflammatory ...